Peptide Research Categories: Mechanisms & Evidence
Peptide research is easier to navigate by the scientific question, tested molecule and measured endpoint than by a claim that one compound “leads” a category. This overview selects examples from tissue repair, neurotrophic signaling, telomere biology, the GH axis and metabolic receptor research. It is not a bibliometric ranking or a clinical treatment framework.
Several categories link to a more detailed evidence review. A supplied reagent must match the original study’s sequence, formulation and analytical requirements before its findings can be transferred to a new experiment.
Quick Reference Matrix
| Research question | Examples and evidence type | Important distinction |
|---|---|---|
| Tendon-cell migration/survival | BPC-157 rat explant/fibroblast work | A cellular endpoint is not clinical healing |
| Actin/wound biology | Full Tβ4 structural/wound studies; some fragment work | TB-500 trade name does not identify a unique sequence |
| Neurotrophic/cognitive signaling | Selected Semax/Selank model literature | Rat gene expression does not establish human cognitive benefit |
| Telomerase/telomeres | Epitalon cell-culture work | Epitalon and Epithalamin extract are not interchangeable |
| Matrix/copper-peptide biology | GHK-Cu fibroblast experiments | Free GHK and copper complex have different masses |
| GH secretion | CJC-1295 DAC and ipamorelin experiments | Class synergy does not validate a particular stack; DAC preserved pulses |
| Metabolic receptor signaling | Retatrutide and other defined incretin agonists | Informal GLP-3 naming requires lot-level identity verification |
These are selected examples, not leaders established by publication counts.
Tissue-Repair / Regeneration Research Category
BPC-157’s rat tendon-cell work supports questions about migration, survival and receptor expression. Full Tβ4’s actin and wound experiments support different questions. The short LKKTETQ fragment has a narrower record and should not inherit every cardiac/corneal finding for full Tβ4.
A mechanism difference can motivate a controlled comparison; it does not establish that a BPC-157/TB-500 stack is superior. See BPC-157 versus TB-500 and the combination review.
Cognitive / Neurotrophic Research Category
Neurotrophic and cognitive research requires especially careful compound and model matching. The Selank 2016 study cited here measured selected neurotransmission-related gene-expression responses in rat frontal cortex. That endpoint does not establish improved cognition or anxiolysis in people.
Likewise, an ACTH-fragment or another peptide’s BDNF result cannot be assigned to every compound placed in a “cognitive” category. Consult the actual sequence, model and behavioral or molecular endpoint before choosing a reagent. This overview does not establish a publication-volume ranking for Semax, Selank, Noopept or other listed tools.
Anti-Aging / Cellular Senescence Research Category
Epitalon has cultured-cell telomerase/telomere findings. Older clinical studies of Epithalamin concern a different pineal preparation. Neither category label establishes human anti-aging efficacy.
GHK-Cu has specific fibroblast matrix-biology findings; it is not established here as a general 4,000-gene “younger transcriptome” treatment.
FOXO4-DRI was investigated in senescence models including aged mice. A senolytic mechanism in those experiments does not demonstrate safe or effective human rejuvenation. See the Epitalon guide and GHK-Cu comparison.
Growth-Hormone-Axis Research Category
The GH-axis examples divide into GHRH analogs and GH-secretagogue/ghrelin-receptor agonists. The 2006 long-acting CJC-1295 DAC studies measured human exposure and GH/IGF-I responses. The follow-up study found preserved GH pulses with higher trough and mean GH.
Ipamorelin has defined cell/animal GH-response and hormone-selectivity experiments. Bowers’ GHRH/GHRP combination studies used specific other interventions; they do not establish that a CJC-1295/ipamorelin pair is the most published or validate its schedule. Mod GRF/no-DAC is a different material from the tested DAC compound. See the GH-axis comparison.
Metabolic / GLP-1-Axis Research Category
Semaglutide, tirzepatide and retatrutide have distinct receptor profiles and pharmaceutical-development histories. Retatrutide is investigational in the cited current publications, with phase 3 results published in 2026; it should not be grouped with approved products merely because trials completed.
A product labelled GLP-3 requires molecular identity checks: the name may refer to retatrutide or another supplied material and is not itself a scientific identifier. A research preparation does not inherit a clinical product’s authorization.
AOD-9604 is a modified C-terminal hGH peptide with a different metabolic research history; it is not an incretin agonist or interchangeable with retatrutide. See the incretin research history and AOD-9604.
How to Choose for Your Research
Select by the actual experiment: identify the relevant original study, molecule, model and endpoint; then compare the supplied lot with those requirements. A trade name, literature-volume assertion or plausible combination is insufficient.
Check sequence/modifications, mass assignment, quantitative content and the quality attributes needed by the assay. Where a proposed combination is the question, include each single compound and a vehicle control. Use the lot reports and purity guide to assess what has actually been measured.
Frequently Asked Questions
The questions below address common orientation issues researchers raise when first navigating the five-category landscape covered in this article. Each answer points to the relevant primary literature or to the deeper review article on this site.
Conclusion
These categories provide orientation, not a ranking of “best” peptides. The reliable unit of evidence is a defined material tested in a defined model with a measured endpoint. Follow the linked reviews and original sources, and verify the supplied lot before treating a pathway hypothesis as a reproduced finding.
Source this peptide for your research
Order BPC-157 at Baltic PeptidesResearch source
Source BPC-157 for your research
Compare available sizes and check the matching batch certificate before ordering.
View productFrequently Asked Questions
How do I decide between two compounds within the same research category?
Compare exact materials and measured endpoints in the intended model. This article does not establish a universal leader, and a difference in mechanism does not prove that a combination is better.
Are these compounds interchangeable in research models?
Do not assume interchangeability by category. Different sequences, modifications or formulations can change the experiment, and a trade name may conceal those differences. Compare the original methods and analytical documentation.
Which research category has the most peer-reviewed literature?
This article has not performed a defined bibliometric count. A defensible ranking would need search terms, databases, date limits, inclusion criteria and deduplication, with separate treatment of reviews and original experiments. The selected examples here should not be presented as measured publication leaders.
What's the difference between research-grade and pharmaceutical peptides?
Research-grade material is supplied for experimental work. A pharmaceutical authorization concerns a defined product, manufacturing controls and indication. HPLC purity and intact mass are useful analytical results, but do not establish clinical approval, net content, sterility or complete sequence confirmation.
Where can I see published research on each compound?
Several category sections link to deeper reviews. For the Selank example, begin with the 2016 rat-frontal-cortex primary reference listed below; that section does not have a separate on-site review link. PubMed (pubmed.ncbi.nlm.nih.gov) is the standard search index for the underlying primary literature, and Google Scholar provides broader coverage including non-English sources for compounds with substantial Russian-language research bases (notably Semax, Selank, Epitalon, and Pinealon). Batch-level analytical data for the research peptides referenced above is published in the Baltic BioLabs lab reports archive.
Is this article a recommendation for using these compounds?
It is an orientation guide to model-specific research evidence. It does not provide a validated regimen or establish that one compound leads a category. For procurement, use the exact protocol and lot documentation; for clinical questions, a research catalogue is not evidence of pharmaceutical authorization.
Scientific References
- Chang 2011. BPC-157 rat tendon-cell findings. PMID: 21030672 - Primary source[PubMed Reference]
- Philp 2003. Tβ4/fragment wound models. PMID: 12581423 - Primary source[PubMed Reference]
- Selank 2016. Rat-cortex gene expression. PMID: 26924987 - Primary source[PubMed Reference]
- Epitalon 2003. Cultured-cell telomerase finding. PMID: 12937682 - Primary source[PubMed Reference]
- Maquart 1988. GHK-Cu fibroblast collagen. PMID: 3169264 - Primary source[PubMed Reference]
- Baar 2017. FOXO4-DRI senescence models. PMID: 28340339 - Primary source[PubMed Reference]
- Ionescu/Frohman 2006. CJC-1295 pulses persist. PMID: 17018654 - Primary source[PubMed Reference]
- Raun 1998. Ipamorelin pharmacology. PMID: 9849822 - Primary source[PubMed Reference]
- Bowers 2004. Specific GHRP-2/GHRH combination. PMID: 15126555 - Primary source[PubMed Reference]
- Coskun 2022. Retatrutide mechanism. PMID: 35985340 - Primary source[PubMed Reference]
- 2026 TRIUMPH-2. PMID: 42810372 - Primary source[PubMed Reference]
Related Research Peptides
BPC-157
Retatrutide
